SBI Life Stock: Motilal Oswal Sees 24% Upside in 2026

Introduction: SBI Life Gains Momentum

Shares of SBI Life Insurance Company Ltd. continued their upward trend on Wednesday, March 18, marking a third consecutive session of gains. The positive sentiment is supported by a reiterated 'Buy' rating from brokerage firm Motilal Oswal Financial Services. The firm has set a price target of ₹2,400 per share, which suggests a potential upside of 24% from the stock's current trading levels. This endorsement comes at a time when the insurer is navigating both strong growth prospects and potential regulatory changes within the Indian insurance sector.

Motilal Oswal's Investment Thesis

Motilal Oswal labels SBI Life a "consistent compounder," highlighting its robust performance relative to the industry. The company's annualised premium equivalent (APE) has grown at a compound annual growth rate (CAGR) of 15% between fiscal years 2020 and 2025. This figure significantly outpaces the overall industry's APE growth of just 6% during the same period. The momentum has carried into the current fiscal year (FY26), with SBI Life reporting 15% year-on-year growth, again ahead of the industry's 13%.

The brokerage anticipates this growth trajectory to remain stable, projecting APE growth to hover around 15% annually through FY28. This sustained performance is expected to be driven by India's structural advantages, including low insurance penetration and a substantial protection gap, which provide a long runway for growth in the life insurance sector.

Strategic Shift in Product Mix

A key driver of SBI Life's profitability has been its strategic pivot in its product portfolio. The company has been consciously reducing its dependence on Unit Linked Insurance Plans (ULIPs), which now constitute around 60% of its business. Instead, the focus has shifted towards more profitable traditional and non-participating (non-par) products. This change is instrumental in enhancing the company's margin profile.

The protection insurance segment, in particular, is showing strong traction. By focusing on higher-margin products, SBI Life aims to create a more resilient business model that is less susceptible to market volatility. This strategic realignment is expected to support stable and gradually improving value of new business (VNB) margins.

VNB Margin and Profitability Outlook

Management has reaffirmed its guidance for VNB margins to remain within a healthy range of 26% to 28% for FY26. This confidence stems from the improving product mix, a higher contribution from protection products, and strong operational efficiencies. Motilal Oswal projects that the VNB margin could reach 28.5% by FY28.

The combination of sustained double-digit premium growth, stable margins, and disciplined cost management is expected to translate into strong returns for shareholders. The brokerage forecasts that SBI Life can deliver an operating return on embedded value (RoEV) of approximately 18% to 19% in the coming years, underscoring its efficient capital utilization and value creation.

Key Financial Performance Metrics

To provide a clearer picture of SBI Life's standing, here is a summary of its key metrics compared to industry peers.

Regulatory Headwinds: The IRDAI Factor

Despite the positive outlook, SBI Life faces potential challenges from regulatory changes. The Insurance Regulatory and Development Authority of India (IRDAI) is considering new rules that could alter how commissions are paid for selling policies. The proposal involves staggering commission payouts over the entire policy term rather than front-loading them. This could impact the new business growth for insurers that rely heavily on bancassurance channels.

Acknowledging this risk, Motilal Oswal recently revised its target price for SBI Life downwards from ₹2,570 to the current ₹2,400. While the 'Buy' rating was maintained, the adjustment reflects the potential for these new regulations to moderate growth in the short term.

Valuation and Peer Comparison

Valuation remains a point of discussion for investors. With a market capitalization of around ₹1.94 trillion, SBI Life trades at a premium compared to some of its peers. Its price-to-earnings (P/E) ratio of approximately 78.16 is higher than that of ICICI Prudential Life but comparable to HDFC Life. This high valuation could pose a risk if growth slows or regulatory headwinds intensify.

Furthermore, while its performance is strong, some metrics lag behind its closest competitor. For instance, HDFC Life reports a higher Return on Equity (ROE) at 17.3% compared to SBI Life's 14.35%. Investors will be closely watching whether SBI Life's strategic initiatives can close this gap.

Future Outlook and Analysis

The consensus among most analysts remains positive, with price targets from other brokerages like Nuvama and JM Financial falling in the ₹2,200-₹2,320 range. The core strengths of SBI Life, including its vast distribution network through its parent, State Bank of India, and its improving product mix, are expected to counteract the challenges.

The primary tasks for the management will be to manage rising operational expenses, which saw a significant 45.6% increase in a recent quarter, and to adapt effectively to any new commission regulations from IRDAI. The company's ability to maintain its growth momentum while navigating these factors will be crucial.

Conclusion

Motilal Oswal's reiterated 'Buy' rating underscores a strong belief in SBI Life's fundamental strengths and its capacity for sustained growth. The 24% upside potential to the ₹2,400 target price presents a compelling case for investors. While regulatory uncertainties and a high valuation warrant caution, the company's consistent outperformance of the industry, strategic product shifts, and robust profitability metrics position it well for the future. Investors should continue to monitor regulatory developments and the company's execution on its margin and growth guidance.